Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Norwegian healthcare region expands enterprise imaging contract with…
Digital pathology leads to numerous advantages for hospitals, pathologists, and patients. Sectra's digital pathology solution will provide Helse Nord RHF with a vendor-neutral and scalable solution that will help minimize time spent on manual processes and strengthen data security. The pathologists will complement their use of microscopes with the digital solution, allowing them to review and collaborate around cases in a way that has not been possible before. They will now have instant and, if…
PR Newswire
09/12/2024
Citryll Raises EUR 85 Million Series B to Advance Novel NET-Targeting Therapy…
CITRYLL RAISES EUR 85 MILLION SERIES B TO ADVANCE NOVEL NET-TARGETING THERAPY FOR IMMUNE-MEDIATED INFLAMMATORY DISORDERSFinancing co-led by Johnson & Johnson Innovation – JJDC, Inc., Forbion and Novartis Venture FundLead first-in-class product candidate, monoclonal antibody CIT-013, to be advanced into two Phase 2a studiesOss, Netherlands – 09 December 2024 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by...
Nasdaq GlobeNewswire
09/12/2024
Crossject and the U.S. Department of Defense Relaunch Joint Research on…
Dijon, France, December 09, 2024, 07:30 CET – Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing the award-winning needle-free ZENEO® autoinjector to deliver life-saving medicines in emergency situations, and the U.S. Department of Defense (DOD), have relaunched their cooperative research on needle-free autoinjectors, signing an extension of their Cooperative Research and Development Agreement (CRADA) from October 2019. As part of the agreement, the DOD...
Nasdaq GlobeNewswire
09/12/2024
Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly…
Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat's Potential to Improve Kidney Function VIVA-MIND Phase 2 data confirm results of varoglutamstat's benefit on eGFR in VIVIAD; Company now has two independent double-blind placebo-controlled Phase 2 studies demonstrating a clinically meaningful treatment effect on kidney functionTopline analysis of kidney function data in VIVA-MIND shows a statistically significant and...
Nasdaq GlobeNewswire
09/12/2024
Five-year results confirm Roche's Polivy combination therapy as new standard of…
Exploratory long-term follow-up analysis of the phase III POLARIX study indicated a positive trend in overall survival in favour of Polivy in combination with R-CHP for people with first-line diffuse large B-cell lymphoma (DLBCL) 1 Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems 1 These encouraging five-year results continue to highlight the potential of this Polivy...
Nasdaq GlobeNewswire
08/12/2024
Longer-term data for Novartis Scemblix® reinforce superior efficacy with…
Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2% vs. 47.1%), meeting both ASC4FIRST 96-week key secondary endpoints1 Scemblix showed a clinically relevant 15.1% higher MMR rate vs. second generation (2G) TKIs (72.0% vs. 56.9%)1 96-week data extend favorable safety and tolerability profile for Scemblix vs. imatinib and 2G TKIs, with fewer grade ≥3 AEs and less than half the...
Nasdaq GlobeNewswire
08/12/2024
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High…
Media ReleaseCOPENHAGEN, Denmark; December 8, 2024 Preliminary analyses from the EPCORE ®CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) who received epcoritamab monotherapyIn the study, 75 percent of evaluable responders achieved undetectable minimal residual disease (MRD), indicating no detectable disease...
Nasdaq GlobeNewswire
08/12/2024
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates…
Media ReleaseCOPENHAGEN, Denmark; December 7, 2024 Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) following treatment with epcoritamab plus lenalidomide + rituximab (R 2 )Long-term follow-up results demonstrated strong and durable efficacy, with an estimated two-year overall survival (OS) rate of 90 percent...
Nasdaq GlobeNewswire
08/12/2024
New Data from PROMMIS Study Highlights the Power of SKY92 in Identifying…
The study [1] included 251 newly diagnosed multiple myeloma patients that were follow up for over nearly four years to monitor their progression. The results showed that individual chromosomal abnormalities and their co-occurrence had limited prognostic value, with the sole exception of the 1q21 abnormality, which prognostic significance for PFS was exclusive to patients aged 65 years and older. SKY92 proved to be a much stronger predictor of poor outcomes. Patients that had the high-risk…
PR Newswire
07/12/2024
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19…
Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging safety profile in all NHL subtypes studied.96% of patients received an infusion of fresh, fit, stem-like, early memory CD19 CAR T-cell therapy with a median vein-to-vein time of seven days, avoiding the need for cryopreservation and bridging therapy.These data reinforce the potential of Galapagos' decentralized cell therapy...
Nasdaq GlobeNewswire
07/12/2024
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in…
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITPPivotal phase 3 data show rapid and durable platelet response, reduced bleeding and need for rescue response, and improved physical fatigue and quality of life measures in patients with persistent or chronic ITPResults underscore the safety and efficacy of rilzabrutinib and its potential as the first BTK inhibitor in ITPRilzabrutinib is currently under regulatory...
Nasdaq GlobeNewswire
07/12/2024
EpiVax Drives Immunogenicity Innovation in 2024: Year in Review
Notably, EpiVax released the ISPRI Downselect™, Quantify™, Analyze™, Evaluate™, Complete™, Optimize™, and Design™ fee-for-service analyses – options that assess biologic modalities at different stages of preclinical development, enabling the ranking of individual candidates, modality-specific benchmarking, sequence optimization and in-depth risk analyses with enhanced accuracy, and more. Class I analysis was also added to the ISPRI toolkit this year for selected gene therapy and CAR-T clients…
PR Newswire
07/12/2024
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial…
Attachments Notification of managers' transaction - Anthony Rosenberg - Dec 2024Notification of managers' transaction - Arshad Khanani - Dec 2024
Nasdaq GlobeNewswire
06/12/2024
NOTICE OF A GENERAL MEETING OF IBA SA
NOTICE OF A GENERAL MEETING OF IBA SA7 January 2025 at 10 a.m. Dear Shareholder,We have the honour of convening you to a General Meeting of IBA (the " GM ") at the Company's [registered office] on7 January 2025 at 10 a.m.in order to deliberate and vote on the items on the attached agenda.The GM will be held in person at the Company's [registered office]. There will also be an online webcast, accessible by prior registration only, but it willnotbepossible to vote online...
Nasdaq GlobeNewswire
06/12/2024
IBA - Regulated Information
IBA SA – Information réglementéeLe 6 décembre 2024,18:00 Publication effectuée en vertu de l'article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes dans des émetteurs dont les actions sont admises à la négociation sur un marché réglementé et portant des dispositions diverses ( M.B. 12.VI.2007 ) (la « Loi ») En vertu de cette disposition :« [...] l'émetteur publie le total du capital, le nombre total de titres conférant le droit de vote et de droits...
Nasdaq GlobeNewswire
06/12/2024
The European Commission approves the acquisition of Catalent by Novo Holdings…
Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings A/S' acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New Jersey (US), as well as Novo Nordisk's subsequent acquisition of three manufacturing sites from Novo Holdings A/S.The agreement to acquire the three manufacturing sites was announced on 5 February 2024. For further information, please seethe company announcement here...
Nasdaq GlobeNewswire
06/12/2024
Spineway provides an update on its activities during a webinar - Arrival of a…
Press release Ecully, December 6, 2024 – 6 p.m.Spineway provides an update on its activities during a webinar Arrival of a new CFO The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, held a webinar on Thursday, December 5, during which Stéphane Le Roux, CEO of Spineway, reviewed the Group's latest developments and confirmed its roadmap for the coming years.The webinar was also an opportunity to present the Group's new Chief...
Nasdaq GlobeNewswire
06/12/2024
Virbac : Declaration of the number of shares and voting rights 11/2024
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers)Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577DateTotal number of shares representing the share capitalTotal number of voting rightsNovember, 30 20248 390 660Gross total of voting...
Nasdaq GlobeNewswire
06/12/2024
IVD Reagents Market to Hit USD 87.41 Million by 2029 with 7.7% CAGR |…
Browse in-depth TOC on "IVD Reagents Market" Browse in-depth TOC on "IVD Reagents Market" 536 - Tables59 - Figures423 - Pages The IVD reagents market is divided into antibodies, antigen, purified proteins, and peptides, oligonucleotides, nucleic acid probes and other IVD reagents based on type. In the year 2023, the IVD reagents market was dominated by the antibodies. The large share of the antibodies is attributed to its wide range of applications in diagnostics...
PR Newswire
06/12/2024
Qi Biodesign Completes $75 Million in Total Funding to Drive Genome Editing…
Qi Biodesign has already achieved significant milestones in product development, including receiving two biosafety certificates for gene-edited plants (high oleic acid soybean and powdery mildew disease-resistant wheat) by the China Ministry of Agriculture and Rural Affairs and securing an exemption for a gene-edited product (high oleic acid soybean) from the US Department of Agriculture. More gene-edited traits including yield enhancements, herbicide tolerance and quality improvements are…
PR Newswire
06/12/2024
OneSight EssilorLuxottica Foundation Joins Forces with World Health Organization…
OneSight EssilorLuxottica Foundation Joins Forces with World Health Organization to Advance Global Vision Care Under WHO SPECS 2030 Initiative Paris, France and Geneva, Switzerland (6 December 2024)– The OneSight EssilorLuxottica Foundation is proud to announce its collaboration with the World Health Organization (WHO) as a global collaborating partner on the WHO's SPECS 2030 initiative.The SPECS initiative builds on the world's first-ever global target to increase effective...
Nasdaq GlobeNewswire
06/12/2024
OneSight EssilorLuxottica Foundation Joins Forces with World Health Organization…
OneSight EssilorLuxottica Foundation Joins Forces with World Health Organization to Advance Global Vision Care Under WHO SPECS 2030 Initiative Paris, France and Geneva, Switzerland (6 December 2024)– The OneSight EssilorLuxottica Foundation is proud to announce its collaboration with the World Health Organization (WHO) as a global collaborating partner on the WHO's SPECS 2030 initiative.The SPECS initiative builds on the world's first-ever global target to increase effective...
Nasdaq GlobeNewswire
06/12/2024
EQT Life Sciences leads Series A funding round for maternal health company Nua…
Barry McCann, CEO of Nua Surgical, commented, "Securing this Series A financing is a crucial milestone for Nua Surgical. It not only provides the capital needed to advance our product but also brings on board a group of experienced investors who share our vision for transforming maternal health. We are eager to leverage their expertise as we move towards commercializing SteriCISION." Barry McCann, CEO of Nua Surgical, commented, "Securing this Series A financing is a crucial…
PR Newswire
06/12/2024
Press Release: Availability of the revised financial statements for Sanofi…
Availability of the revised financial statements for Sanofi excluding OpellaParis, France – December 6, 2024. Following thepress releaseon October 21, 2024 and the plan to transfer a 50% controlling stake in Opella (consumer healthcare division) to CD&R, the revised financial statements for Sanofi reflecting the new scope, excluding Opella, are now available on the"Investors" section of sanofi.comin one convenient spreadsheet file.The adjustments to the financial statements...
Nasdaq GlobeNewswire
06/12/2024
Altri Comunicati
